Pevaryl Cutaneous Solution 6 Sachets 10 g 1%

Product details

Therapeutic indications
Pevaryl Cutaneous Solution is used in the treatment of:

cutaneous mycoses caused by dermatophytes, yeasts and molds
skin infections caused by Gram-positive bacteria: streptococci and staphylococci
mycotic otitis externa, mycosis of the ear canal (limited to the skin emulsion form)
onychomycosis
Pityriasis Versicolor

Dosage and method of use
Pevaryl must be applied morning and evening, in the infected skin areas, with a light massage, until the mycosis has completely disappeared (1-3 weeks). It is advisable to continue the application of Pevaryl for a few days after the disappearance of the mycosis.

Intertriginous spaces (e.g. interdigital spaces of the foot, folds of the buttocks) in the wet stage should be cleansed with gauze prior to applying Pevaryl. An occlusive dressing is recommended in the treatment of onychomycosis. Pevaryl non-alcoholic cutaneous solution: sprinkle, for three consecutive evenings, the whole wet body by placing the product on a sponge; do not rinse. The drug works during the night and must be washed off the following morning. If after 15 days from the end of the applications the Pityriasis Versicolor is not eradicated, repeat the treatment. To avoid relapses yes
recommends carrying out the treatment again after 1 and 3 months. The regular and prescribed use of Pevaryl is of decisive importance for the
healing.

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Special warnings
All pharmaceutical forms of Pevaryl are indicated for external use only. Pevaryl is not for ophthalmic or oral use. In case of sensitization or irritation reaction, discontinue use of the product. Econazole nitrate powder contains talc. Avoid inhalation to prevent irritation of the airways, especially in children and infants.

The application of the spray forms must be done avoiding inhaling the product and making excessive and improper use of it.

Pregnancy and breastfeeding

Pregnancy

In animal studies econazole nitrate did not show teratogenic effects but did show foetotoxic effects in rodents at maternal subcutaneous doses of 20 mg / kg / day and maternal oral doses of 10 mg / kg / day. The relevance of this effect in humans is unknown. In humans, after topical application to intact skin, the systemic absorption of econazole is poor (<10%). There are no adequate and controlled studies, nor epidemiological data, on the undesirable effects resulting from the use of Pevaryl in pregnancy. In post-marketing studies, no adverse effects on pregnancy or on the health of the fetus and newborn were reported due to Pevaryl. Due to systemic absorption, Pevaryl should not be used during the first trimester of pregnancy unless the doctor considers it necessary for the patient's health. Pevaryl can be used during the second and third trimester of pregnancy if the potential benefit to the mother outweighs the possible risks to the fetus.

Feeding time

After oral administration of econazole nitrate to lactating rats, econazole and / or its metabolites were excreted in breast milk and detected in pups. It is unknown whether dermal administration of Pevaryl can result in sufficient systemic absorption of econazole to produce detectable concentrations of econazole in human breast milk. Caution should be exercised when Pevaryl is administered to breastfeeding women.

Expiry and retention.
Check the expiration date indicated on the package. The expiry date indicated on the package refers to the product in intact packaging, correctly stored. Store at a temperature not exceeding 25 ° C.

Warning: do not use the medicine after the expiry date indicated on the package.

Composition
Pevaryl Cutaneous Solution contains:
Active ingredient: econazole 1.0 g
Excipients: polysorbate 20; benzyl alcohol; sorbitan monolaurate; N- [2-hydroxyethyl] -N- [2- (laurylamino) -ethyl] amino acetic acid sodium salt of 3,6,9-trioxadocosyl sulfate; polyoxyethylene glycol 6000 distearate; purified water.